Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FATE |
---|---|---|
09:32 ET | 33133 | 4.35 |
09:34 ET | 3301 | 4.375 |
09:36 ET | 10987 | 4.315 |
09:38 ET | 7500 | 4.29 |
09:39 ET | 16674 | 4.24 |
09:41 ET | 2535 | 4.23 |
09:43 ET | 7238 | 4.23 |
09:45 ET | 6116 | 4.22 |
09:48 ET | 6480 | 4.23 |
09:50 ET | 1535 | 4.215 |
09:52 ET | 8258 | 4.21 |
09:54 ET | 2396 | 4.215 |
09:56 ET | 3152 | 4.2 |
09:57 ET | 4214 | 4.17 |
09:59 ET | 6139 | 4.17 |
10:01 ET | 9230 | 4.195 |
10:03 ET | 2021 | 4.21 |
10:06 ET | 13835 | 4.215 |
10:08 ET | 3578 | 4.21 |
10:10 ET | 1555 | 4.205 |
10:12 ET | 10682 | 4.205 |
10:14 ET | 7225 | 4.215 |
10:15 ET | 5426 | 4.2 |
10:17 ET | 6525 | 4.195 |
10:19 ET | 5636 | 4.18 |
10:21 ET | 13058 | 4.175 |
10:24 ET | 6818 | 4.165 |
10:26 ET | 6488 | 4.175 |
10:28 ET | 2489 | 4.175 |
10:30 ET | 4522 | 4.1799 |
10:32 ET | 7558 | 4.176 |
10:33 ET | 34720 | 4.125 |
10:35 ET | 5138 | 4.125 |
10:37 ET | 10719 | 4.13 |
10:39 ET | 38046 | 4.1 |
10:42 ET | 9298 | 4.12 |
10:44 ET | 13398 | 4.14 |
10:46 ET | 7444 | 4.135 |
10:48 ET | 4711 | 4.14 |
10:50 ET | 6489 | 4.125 |
10:51 ET | 3862 | 4.125 |
10:53 ET | 1730 | 4.125 |
10:55 ET | 11074 | 4.135 |
10:57 ET | 7290 | 4.15 |
11:00 ET | 7658 | 4.145 |
11:02 ET | 6965 | 4.145 |
11:04 ET | 6100 | 4.135 |
11:06 ET | 600 | 4.13 |
11:08 ET | 1535 | 4.13 |
11:09 ET | 7095 | 4.135 |
11:11 ET | 1316 | 4.135 |
11:13 ET | 2405 | 4.135 |
11:15 ET | 3048 | 4.135 |
11:18 ET | 3934 | 4.125 |
11:20 ET | 6150 | 4.125 |
11:22 ET | 1757 | 4.125 |
11:24 ET | 1516 | 4.125 |
11:26 ET | 2674 | 4.125 |
11:27 ET | 4012 | 4.125 |
11:29 ET | 12931 | 4.145 |
11:31 ET | 36977 | 4.12 |
11:33 ET | 3130 | 4.116 |
11:36 ET | 3415 | 4.125 |
11:38 ET | 2750 | 4.13 |
11:40 ET | 4485 | 4.13 |
11:42 ET | 3097 | 4.115 |
11:44 ET | 1600 | 4.12 |
11:45 ET | 884 | 4.115 |
11:47 ET | 2673 | 4.115 |
11:49 ET | 3717 | 4.125 |
11:51 ET | 600 | 4.14 |
11:54 ET | 2496 | 4.14 |
11:56 ET | 795 | 4.135 |
11:58 ET | 1900 | 4.14 |
12:00 ET | 400 | 4.135 |
12:02 ET | 4421 | 4.125 |
12:03 ET | 3920 | 4.135 |
12:05 ET | 400 | 4.145 |
12:07 ET | 1010 | 4.15 |
12:09 ET | 400 | 4.14 |
12:12 ET | 1066 | 4.145 |
12:14 ET | 498 | 4.14 |
12:16 ET | 14457 | 4.125 |
12:18 ET | 617 | 4.125 |
12:20 ET | 1773 | 4.125 |
12:21 ET | 4363 | 4.125 |
12:23 ET | 1701 | 4.125 |
12:25 ET | 20944 | 4.155 |
12:27 ET | 64631 | 4.155 |
12:30 ET | 13424 | 4.16 |
12:32 ET | 29746 | 4.165 |
12:34 ET | 35924 | 4.155 |
12:36 ET | 795 | 4.155 |
12:38 ET | 18698 | 4.15 |
12:39 ET | 27026 | 4.18 |
12:41 ET | 7293 | 4.2 |
12:43 ET | 4925 | 4.21 |
12:45 ET | 3855 | 4.205 |
12:48 ET | 34591 | 4.21 |
12:50 ET | 1000 | 4.215 |
12:52 ET | 19606 | 4.215 |
12:54 ET | 2707 | 4.215 |
12:56 ET | 2051 | 4.215 |
12:57 ET | 5284 | 4.215 |
12:59 ET | 14180 | 4.225 |
01:01 ET | 4897 | 4.23 |
01:03 ET | 3944 | 4.225 |
01:06 ET | 25836 | 4.225 |
01:08 ET | 2491 | 4.225 |
01:10 ET | 6415 | 4.225 |
01:12 ET | 8885 | 4.215 |
01:14 ET | 14970 | 4.215 |
01:15 ET | 20182 | 4.215 |
01:17 ET | 1304 | 4.215 |
01:19 ET | 8444 | 4.22 |
01:21 ET | 3054 | 4.225 |
01:24 ET | 5535 | 4.225 |
01:26 ET | 6579 | 4.225 |
01:28 ET | 8292 | 4.23 |
01:30 ET | 3504 | 4.225 |
01:32 ET | 1057 | 4.225 |
01:33 ET | 3111 | 4.225 |
01:35 ET | 3406 | 4.225 |
01:37 ET | 300 | 4.22 |
01:39 ET | 9103 | 4.21 |
01:42 ET | 1811 | 4.215 |
01:44 ET | 2972 | 4.215 |
01:46 ET | 4734 | 4.215 |
01:48 ET | 3906 | 4.215 |
01:50 ET | 4214 | 4.215 |
01:51 ET | 4000 | 4.215 |
01:53 ET | 17510 | 4.205 |
01:55 ET | 5661 | 4.2 |
01:57 ET | 6084 | 4.215 |
02:00 ET | 11870 | 4.2 |
02:02 ET | 1417 | 4.21 |
02:04 ET | 2681 | 4.205 |
02:06 ET | 2647 | 4.205 |
02:08 ET | 1600 | 4.205 |
02:09 ET | 3134 | 4.205 |
02:11 ET | 2300 | 4.205 |
02:13 ET | 12168 | 4.23 |
02:15 ET | 20615 | 4.235 |
02:18 ET | 2809 | 4.235 |
02:20 ET | 1300 | 4.235 |
02:22 ET | 4602 | 4.24 |
02:24 ET | 16437 | 4.225 |
02:26 ET | 1700 | 4.225 |
02:27 ET | 3466 | 4.225 |
02:29 ET | 2998 | 4.22 |
02:31 ET | 1300 | 4.225 |
02:33 ET | 2874 | 4.22 |
02:36 ET | 5595 | 4.23 |
02:38 ET | 1336 | 4.23 |
02:40 ET | 8305 | 4.21 |
02:42 ET | 17644 | 4.225 |
02:44 ET | 15663 | 4.245 |
02:45 ET | 157124 | 4.245 |
02:47 ET | 18773 | 4.27 |
02:49 ET | 3444 | 4.27 |
02:51 ET | 3537 | 4.265 |
02:54 ET | 4335 | 4.26 |
02:56 ET | 1450 | 4.26 |
02:58 ET | 21165 | 4.265 |
03:00 ET | 2055 | 4.26 |
03:02 ET | 2306 | 4.26 |
03:03 ET | 8685 | 4.26 |
03:05 ET | 3852 | 4.255 |
03:07 ET | 7675 | 4.26 |
03:09 ET | 6776 | 4.255 |
03:12 ET | 2128 | 4.25 |
03:14 ET | 3402 | 4.255 |
03:16 ET | 4639 | 4.255 |
03:18 ET | 2223 | 4.25 |
03:20 ET | 2964 | 4.25 |
03:21 ET | 47629 | 4.27 |
03:23 ET | 9673 | 4.255 |
03:25 ET | 9508 | 4.26 |
03:27 ET | 7218 | 4.25 |
03:30 ET | 9016 | 4.255 |
03:32 ET | 13741 | 4.265 |
03:34 ET | 5543 | 4.2699 |
03:36 ET | 22660 | 4.275 |
03:38 ET | 25349 | 4.26 |
03:39 ET | 3997 | 4.26 |
03:41 ET | 4873 | 4.265 |
03:43 ET | 40654 | 4.265 |
03:45 ET | 59331 | 4.26 |
03:48 ET | 61856 | 4.24 |
03:50 ET | 9550 | 4.24 |
03:52 ET | 11467 | 4.24 |
03:54 ET | 31640 | 4.215 |
03:56 ET | 81245 | 4.205 |
03:57 ET | 41448 | 4.22 |
03:59 ET | 206803 | 4.22 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Fate Therapeutics Inc | 480.3M | -2.2x | --- |
Editas Medicine Inc | 467.1M | -2.7x | --- |
ADC Therapeutics SA | 388.6M | -1.5x | --- |
Urogen Pharma Ltd | 468.6M | -3.8x | --- |
Contineum Therapeutics Inc | 404.5M | 17.1x | --- |
Y-mAbs Therapeutics Inc | 518.6M | -23.8x | --- |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $480.3M |
---|---|
Revenue (TTM) | $6.5M |
Shares Outstanding | 113.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.94 |
EPS | $-1.92 |
Book Value | $3.74 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 74.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,287.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.